Abstract Background and Aim The epithelial–mesenchymal transition (EMT) of hepatocytes
is a key step for hepatic fibrosis and cirrhosis. Long‐term administration of celecoxib, a …

Background Increased intra-hepatic resistance to portal blood flow is the primary factor
leading to portal hypertension in cirrhosis. Up-regulated expression of cyclooxygenase-2 …

Background & aims Splenomegaly is usually taken as a consequence of liver cirrhosis.
However, as a risk factor for cirrhosis, the impacts of spleen-liver axis on the development of …

Background and aims: Activated hepatic stellate cells (HSCs) but not quiescent HSCs
express cyclo-oxygenase-2 (COX-2), suggesting that the COX-2/prostanoid pathway has an …

Hepatic stellate cells (HSCs) play a critical role in the fibrogenesis of the liver, so they are
the target cells of antifibrotic therapy. Activated HSCs, but not quiescent HSCs, express …

Background/Aim: Cyclooxygenase‐2 (COX‐2), an inducible enzyme that catalyzes
prostaglandin synthesis, has been implicated in a number of hepatic stellate cell (HSC) …

BACKGROUND Endoplasmic reticulum (ER) stress is an important mechanism in the
progression of chronic and acute liver diseases, especially in the progression and recovery …

Inflammatory transport through the gut-liver axis may facilitate liver cirrhosis.
Cyclooxygenase-2 (COX-2) has been considered as one of the important molecules that …

Abnormal angiogenesis is critical for portal hypertension in cirrhosis. Except for etiological
treatment, no efficient medication or regime has been explored to treat the early stage of …

Abstract Background/Aims: Celecoxib was used in the treatment of inflammation in patients
with cirrhosis. However, data on the progression of liver fibrosis after treatment by celecoxib …